cyc 202 has been researched along with clozapine in 8 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 9,691 | 747 | 3,148 |
| Protein | Taxonomy | cyc 202 (IC50) | clozapine (IC50) |
|---|---|---|---|
| Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
| D | Rattus norvegicus (Norway rat) | 1.066 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
| Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
| Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
| Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
| Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
| D | Bos taurus (cattle) | 4.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
8 other study(ies) available for cyc 202 and clozapine
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |